TY - JOUR
T1 - Annexin A1'containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair
AU - Leoni, Giovanna
AU - Neumann, Philipp Alexander
AU - Kamaly, Nazila
AU - Quiros, Miguel
AU - Nishio, Hikaru
AU - Jones, Hefin R.
AU - Sumagin, Ronen
AU - Hilgarth, Roland S.
AU - Alam, Ashfaqul
AU - Fredman, Gabrielle
AU - Argyris, Ioannis
AU - Rijcken, Emile
AU - Kusters, Dennis
AU - Reutelingsperger, Chris
AU - Perretti, Mauro
AU - Parkos, Charles A.
AU - Farokhzad, Omid C.
AU - Neish, Andrew S.
AU - Nusrat, Asma
PY - 2015/3/2
Y1 - 2015/3/2
N2 - Epithelial restitution is an essential process that is required to repair barrier function at mucosal surfaces following injury. Prolonged breaches in epithelial barrier function result in inflammation and further damage; therefore, a better understanding of the epithelial restitution process has potential for improving the development of therapeutics. In this work, we demonstrate that endogenous annexin A1 (ANXA1) is released as a component of extracellular vesicles (EVs) derived from intestinal epithelial cells, and these ANXA1-containing EVs activate wound repair circuits. Compared with healthy controls, patients with active inflammatory bowel disease had elevated levels of secreted ANXA1-containing EVs in sera, indicating that ANXA1-containing EVs are systemically distributed in response to the inflammatory process and could potentially serve as a biomarker of intestinal mucosal inflammation. Local intestinal delivery of an exogenous ANXA1 mimetic peptide (Ac2-26) encapsulated within targeted polymeric nanoparticles (Ac2-26 Col IV NPs) accelerated healing of murine colonic wounds after biopsy-induced injury. Moreover, one-time systemic administration of Ac2-26 Col IV NPs accelerated recovery following experimentally induced colitis. Together, our results suggest that local delivery of proresolving peptides encapsulated within nanoparticles may represent a potential therapeutic strategy for clinical situations characterized by chronic mucosal injury, such as is seen in patients with IBD.
AB - Epithelial restitution is an essential process that is required to repair barrier function at mucosal surfaces following injury. Prolonged breaches in epithelial barrier function result in inflammation and further damage; therefore, a better understanding of the epithelial restitution process has potential for improving the development of therapeutics. In this work, we demonstrate that endogenous annexin A1 (ANXA1) is released as a component of extracellular vesicles (EVs) derived from intestinal epithelial cells, and these ANXA1-containing EVs activate wound repair circuits. Compared with healthy controls, patients with active inflammatory bowel disease had elevated levels of secreted ANXA1-containing EVs in sera, indicating that ANXA1-containing EVs are systemically distributed in response to the inflammatory process and could potentially serve as a biomarker of intestinal mucosal inflammation. Local intestinal delivery of an exogenous ANXA1 mimetic peptide (Ac2-26) encapsulated within targeted polymeric nanoparticles (Ac2-26 Col IV NPs) accelerated healing of murine colonic wounds after biopsy-induced injury. Moreover, one-time systemic administration of Ac2-26 Col IV NPs accelerated recovery following experimentally induced colitis. Together, our results suggest that local delivery of proresolving peptides encapsulated within nanoparticles may represent a potential therapeutic strategy for clinical situations characterized by chronic mucosal injury, such as is seen in patients with IBD.
UR - http://www.scopus.com/inward/record.url?scp=84924066805&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924066805&partnerID=8YFLogxK
U2 - 10.1172/JCI76693
DO - 10.1172/JCI76693
M3 - Article
C2 - 25664854
AN - SCOPUS:84924066805
SN - 0021-9738
VL - 125
SP - 1215
EP - 1227
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 3
ER -